NCT00795574View on ClinicalTrials.gov

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

infliximab

Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.

DRUG

Placebo Comparator

5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.

Trial Locations (1)

33143

Florida Academic Dermatology Center, Miami

All Listed Sponsors
lead

Florida Academic Dermatology Centers

OTHER

NCT00795574 - Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa | Biotech Hunter | Biotech Hunter